QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NYSE:HAE

Haemonetics - HAE Stock Forecast, Price & News

$76.32
+0.44 (+0.58%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$75.41
$76.67
50-Day Range
$59.28
$75.88
52-Week Range
$43.50
$77.08
Volume
312,384 shs
Average Volume
508,275 shs
Market Capitalization
$3.92 billion
P/E Ratio
58.26
Dividend Yield
N/A
Price Target
$82.80

Haemonetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
8.5% Upside
$82.80 Price Target
Short Interest
Healthy
3.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.42mentions of Haemonetics in the last 14 days
Based on 31 Articles This Week
Insider Trading
Selling Shares
$1.07 M Sold Last Quarter
Proj. Earnings Growth
7.94%
From $2.77 to $2.99 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

728th out of 1,124 stocks

Surgical & Medical Instruments Industry

66th out of 113 stocks

HAE stock logo

About Haemonetics (NYSE:HAE) Stock

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Haemonetics Trading Up 0.6 %

NYSE:HAE traded up $0.46 during trading hours on Tuesday, reaching $76.34. The company's stock had a trading volume of 6,847 shares, compared to its average volume of 385,893. The firm has a fifty day simple moving average of $66.19 and a 200-day simple moving average of $60.13. The stock has a market cap of $3.92 billion, a P/E ratio of 58.34 and a beta of 0.39. Haemonetics has a 52 week low of $43.50 and a 52 week high of $77.08. The company has a debt-to-equity ratio of 0.99, a current ratio of 3.81 and a quick ratio of 2.27.

Haemonetics (NYSE:HAE - Get Rating) last issued its quarterly earnings data on Wednesday, August 10th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.07. The business had revenue of $261.50 million during the quarter, compared to analyst estimates of $249.00 million. Haemonetics had a net margin of 6.60% and a return on equity of 18.62%. The firm's quarterly revenue was up 14.4% on a year-over-year basis. During the same quarter last year, the business earned $0.50 EPS. Equities analysts forecast that Haemonetics will post 2.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HAE has been the topic of several analyst reports. Barrington Research upped their price target on shares of Haemonetics from $77.00 to $88.00 and gave the stock an "outperform" rating in a research report on Thursday, August 11th. Citigroup upped their price target on shares of Haemonetics to $74.00 in a research report on Monday. StockNews.com raised shares of Haemonetics from a "hold" rating to a "buy" rating in a research report on Thursday, July 21st. Morgan Stanley upped their price objective on shares of Haemonetics from $70.00 to $74.00 and gave the company an "equal weight" rating in a report on Thursday, August 11th. Finally, Raymond James upped their price objective on shares of Haemonetics from $76.00 to $88.00 and gave the company an "outperform" rating in a report on Thursday, August 11th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Haemonetics presently has an average rating of "Moderate Buy" and an average price target of $82.80.

Insider Buying and Selling at Haemonetics

In other Haemonetics news, CEO Christopher Simon sold 1,148 shares of the stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $62.60, for a total transaction of $71,864.80. Following the completion of the sale, the chief executive officer now owns 213,724 shares of the company's stock, valued at approximately $13,379,122.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Haemonetics news, CEO Christopher Simon sold 1,148 shares of the stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $62.60, for a total transaction of $71,864.80. Following the completion of the sale, the chief executive officer now owns 213,724 shares of the company's stock, valued at approximately $13,379,122.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stewart W. Strong sold 1,084 shares of the stock in a transaction that occurred on Thursday, May 19th. The shares were sold at an average price of $59.10, for a total transaction of $64,064.40. Following the sale, the insider now directly owns 15,756 shares of the company's stock, valued at approximately $931,179.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 7,075 shares of company stock valued at $425,274. 1.65% of the stock is currently owned by company insiders.

Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Stock News Headlines

Haemonetics: Q1 Earnings Insights - Benzinga
Analysts Set Haemonetics Co. (NYSE:HAE) Target Price at $72.40
Haemonetics (HAE) to Release Quarterly Earnings on Wednesday
See More Headlines
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Company Calendar

Last Earnings
8/10/2022
Today
8/16/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
CUSIP
40502410
Employees
2,821
Year Founded
1971

Price Target and Rating

Average Stock Price Forecast
$82.80
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$74.00
Forecasted Upside/Downside
+8.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$43.38 million
Pretax Margin
8.98%

Debt

Sales & Book Value

Annual Sales
$993.20 million
Cash Flow
$4.64 per share
Book Value
$14.66 per share

Miscellaneous

Free Float
50,470,000
Market Cap
$3.92 billion
Optionable
Optionable
Beta
0.39

Social Links















HAE Stock - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price forecast for 2022?

6 equities research analysts have issued 1-year target prices for Haemonetics' stock. Their HAE share price forecasts range from $74.00 to $90.00. On average, they expect the company's share price to reach $82.80 in the next year. This suggests a possible upside of 8.5% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2022?

Haemonetics' stock was trading at $53.04 at the start of the year. Since then, HAE stock has increased by 43.9% and is now trading at $76.32.
View the best growth stocks for 2022 here
.

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our HAE earnings forecast
.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) announced its quarterly earnings results on Wednesday, August, 10th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.51 by $0.07. The medical instruments supplier earned $261.50 million during the quarter, compared to the consensus estimate of $249 million. Haemonetics had a net margin of 6.60% and a trailing twelve-month return on equity of 18.62%. The company's revenue for the quarter was up 14.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.50 earnings per share.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY 2023 earnings guidance on Friday, August, 12th. The company provided earnings per share (EPS) guidance of $2.60-$2.90 for the period, compared to the consensus estimate of $2.73. The company issued revenue guidance of $1.07 billion-$1.10 billion, compared to the consensus revenue estimate of $1.06 billion.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include LGT Capital Partners LTD. (1.93%), Royce & Associates LP (1.64%), Northern Trust Corp (1.29%), Boston Trust Walden Corp (1.19%), River Road Asset Management LLC (0.91%) and Point72 Asset Management L.P. (0.80%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh, Stewart W Strong and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $76.32.

How much money does Haemonetics make?

Haemonetics (NYSE:HAE) has a market capitalization of $3.92 billion and generates $993.20 million in revenue each year. The medical instruments supplier earns $43.38 million in net income (profit) each year or $1.31 on an earnings per share basis.

How many employees does Haemonetics have?

The company employs 2,821 workers across the globe.

When was Haemonetics founded?

Haemonetics was founded in 1971.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.

This page (NYSE:HAE) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.